|
Gene: IGKC |
Gene summary for IGKC |
Gene summary. |
Gene information | Species | Human | Gene symbol | IGKC | Gene ID | 3514 |
Gene name | immunoglobulin kappa constant | |
Gene Alias | HCAK1 | |
Cytomap | 2p11.2 | |
Gene Type | other | GO ID | GO:0001775 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3514 | IGKC | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.52e-21 | 3.12e+00 | 0.3487 |
3514 | IGKC | A002-C-201 | Human | Colorectum | FAP | 1.92e-04 | -1.69e-01 | 0.0324 |
3514 | IGKC | A002-C-205 | Human | Colorectum | FAP | 1.87e-02 | -1.51e-01 | -0.1236 |
3514 | IGKC | A002-C-016 | Human | Colorectum | FAP | 3.18e-02 | -1.25e-01 | 0.0521 |
3514 | IGKC | A001-C-203 | Human | Colorectum | FAP | 2.51e-02 | -1.57e-01 | -0.0481 |
3514 | IGKC | A002-C-116 | Human | Colorectum | FAP | 1.55e-02 | -1.28e-01 | -0.0452 |
3514 | IGKC | A018-E-020 | Human | Colorectum | FAP | 1.39e-03 | -1.69e-01 | -0.2034 |
3514 | IGKC | CRC-3-11773 | Human | Colorectum | CRC | 3.06e-02 | -1.65e-01 | 0.2564 |
3514 | IGKC | AEH-subject1 | Human | Endometrium | AEH | 9.15e-10 | 3.83e-01 | -0.3059 |
3514 | IGKC | AEH-subject2 | Human | Endometrium | AEH | 6.59e-04 | 6.08e-01 | -0.2525 |
3514 | IGKC | AEH-subject4 | Human | Endometrium | AEH | 4.89e-09 | 5.59e-01 | -0.2657 |
3514 | IGKC | EEC-subject1 | Human | Endometrium | EEC | 1.00e-02 | 4.43e-04 | -0.2682 |
3514 | IGKC | EEC-subject2 | Human | Endometrium | EEC | 6.84e-46 | 9.29e-01 | -0.2607 |
3514 | IGKC | EEC-subject3 | Human | Endometrium | EEC | 1.81e-47 | 1.33e+00 | -0.2525 |
3514 | IGKC | EEC-subject4 | Human | Endometrium | EEC | 3.78e-111 | 1.63e+00 | -0.2571 |
3514 | IGKC | EEC-subject5 | Human | Endometrium | EEC | 2.12e-52 | 1.19e+00 | -0.249 |
3514 | IGKC | GSM5276934 | Human | Endometrium | EEC | 1.82e-05 | -9.14e-02 | -0.0913 |
3514 | IGKC | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 7.40e-03 | -9.14e-02 | -0.1934 |
3514 | IGKC | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 7.40e-03 | -9.14e-02 | -0.1917 |
3514 | IGKC | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.73e-02 | -9.14e-02 | -0.1916 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000189511 | Breast | IDC | retina homeostasis | 15/1434 | 79/18723 | 8.62e-04 | 1.00e-02 | 15 |
GO:00069596 | Breast | IDC | humoral immune response | 40/1434 | 317/18723 | 1.25e-03 | 1.33e-02 | 40 |
GO:000189413 | Breast | IDC | tissue homeostasis | 34/1434 | 268/18723 | 2.54e-03 | 2.28e-02 | 34 |
GO:00512515 | Breast | IDC | positive regulation of lymphocyte activation | 43/1434 | 362/18723 | 2.72e-03 | 2.41e-02 | 43 |
GO:00022532 | Breast | IDC | activation of immune response | 43/1434 | 375/18723 | 5.16e-03 | 3.84e-02 | 43 |
GO:00026966 | Breast | IDC | positive regulation of leukocyte activation | 46/1434 | 409/18723 | 5.60e-03 | 4.07e-02 | 46 |
GO:000189521 | Breast | DCIS | retina homeostasis | 14/1390 | 79/18723 | 1.88e-03 | 1.81e-02 | 14 |
GO:005125111 | Breast | DCIS | positive regulation of lymphocyte activation | 42/1390 | 362/18723 | 2.65e-03 | 2.35e-02 | 42 |
GO:000189423 | Breast | DCIS | tissue homeostasis | 33/1390 | 268/18723 | 2.88e-03 | 2.48e-02 | 33 |
GO:000225311 | Breast | DCIS | activation of immune response | 43/1390 | 375/18723 | 2.96e-03 | 2.54e-02 | 43 |
GO:000695911 | Breast | DCIS | humoral immune response | 37/1390 | 317/18723 | 4.16e-03 | 3.29e-02 | 37 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00018949 | Cervix | CC | tissue homeostasis | 57/2311 | 268/18723 | 2.43e-05 | 4.21e-04 | 57 |
GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
GO:0002768 | Cervix | CC | immune response-regulating cell surface receptor signaling pathway | 59/2311 | 315/18723 | 6.64e-04 | 6.11e-03 | 59 |
GO:00026967 | Cervix | CC | positive regulation of leukocyte activation | 72/2311 | 409/18723 | 1.13e-03 | 9.31e-03 | 72 |
GO:00512516 | Cervix | CC | positive regulation of lymphocyte activation | 65/2311 | 362/18723 | 1.15e-03 | 9.39e-03 | 65 |
GO:00508676 | Cervix | CC | positive regulation of cell activation | 73/2311 | 420/18723 | 1.50e-03 | 1.16e-02 | 73 |
GO:00018957 | Cervix | CC | retina homeostasis | 19/2311 | 79/18723 | 2.94e-03 | 1.94e-02 | 19 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGKC | SNV | Missense_Mutation | novel | c.63A>C | p.Thr22Pro | p.T22P | IG_C_gene | tolerated(0.15) | possibly_damaging(0.73) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
IGKC | SNV | Missense_Mutation | novel | c.161N>C | p.Glu54Asp | p.E54D | IG_C_gene | tolerated(0.36) | benign(0) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.90N>G | p.Asn31Asp | p.N31D | IG_C_gene | tolerated(0.57) | benign(0.007) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.154N>A | p.Ser52Tyr | p.S52Y | IG_C_gene | deleterious(0) | benign(0.065) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | rs373698975 | c.145N>T | p.Ser49Leu | p.S49L | IG_C_gene | deleterious(0.05) | benign(0.418) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
IGKC | SNV | Missense_Mutation | novel | c.58N>A | p.Ser20Tyr | p.S20Y | IG_C_gene | deleterious(0) | probably_damaging(0.938) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
IGKC | SNV | Missense_Mutation | novel | c.141C>A | p.Gln48Lys | p.Q48K | IG_C_gene | tolerated(0.65) | benign(0.013) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.61N>A | p.Gly21Glu | p.G21E | IG_C_gene | deleterious(0.05) | possibly_damaging(0.777) | TCGA-NJ-A4YG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.217N>A | p.Thr73Lys | p.T73K | IG_C_gene | deleterious(0) | possibly_damaging(0.893) | TCGA-39-5016-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
IGKC | SNV | Missense_Mutation | novel | c.274N>G | p.Gln92Arg | p.Q92R | IG_C_gene | tolerated(0.06) | benign(0.03) | TCGA-63-A5MI-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | vinorelbine | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |